Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging
Purpose/Objective(s): Over 30% of advanced prostate cancers harbor a predominance of neuroendocrine prostate cancer (NEPC) differentiation. Fluorodeoxyglucose (FDG) positron emission tomography (PET) has numerous limitations in prostate adenocarcinoma (PCa-adeno), however there is no data that exists outside of isolated single person case reports to assess the utility of PET to restage and monitor
